The rapid rise of nicotine pouch consumption has prompted tobacco manufacturers to pour considerable capital into U.S. manufacturing facilities, generating employment opportunities across states such as Florida and Colorado.
Combined with vaping devices, major tobacco corporations view the pouch segment as a strategic avenue to counterbalance the pronounced drop in domestic cigarette sales.
Industry forecasts estimate global pouch revenues will surpass $40 billion by 2033, up from $6.9 billion in 2025, according to a Grand View Research study.
To satisfy this burgeoning demand, firms have already invested over $1 billion in new plant infrastructure. Numerous states have embraced these expansions, offering multi‑million‑dollar tax incentives and grants.
Nevertheless, positioning nicotine‑laden products — such as pouches, gums, and lozenges — as ostensibly safer alternatives to cigarettes has sparked heightened public‑health apprehension.
Experts contend that the industry is once again disregarding extensive research demonstrating nicotine’s addictive properties, while deliberately engineering increasingly potent formulations to sustain demand.
Echoing the controversy surrounding Juul and other flavored vaping products that sparked public outcry over adolescent use, these tobacco‑free “lip pillows” have reignited concerns that nicotine is highly addictive and may precipitate conditions such as anxiety and cardiac arrhythmia. Moreover, the still‑developing adolescent brain faces potential impacts on behavior and cognitive performance, according to specialists.
Colorado Governor Jared Polis, a Democrat, defended the state’s support for a $600 million Aurora facility constructed by Philip Morris International, which has received $4.5 million in state tax credits.
“As the first state to legalize marijuana, we now operate more than 650 dispensaries, have embraced natural‑medicine initiatives, and host nearly 50 regulated therapeutic centers offering psilocybin,” Governor Polis remarked. “Consequently, we actively encourage safer smoking alternatives, such as Zyn, within our jurisdiction.”
These expansions underscore the tobacco sector’s growing influence on the evolving discourse surrounding the safety of this next‑generation product category.
Having contributed substantially to President Trump’s campaigns, the industry has experienced a comparatively more receptive regulatory environment under his administration than under preceding presidents.
In May, the U.S. Food and Drug Administration released updated guidance that relaxes certain regulations on nicotine pouches and vaping products, occurring just one week after Reynolds America contributed $5 million to a super PAC supportive of President Trump.
In late June, the FDA announced its intention to permit select Zyn products to be marketed as presenting reduced risk for certain cancers and diseases relative to conventional cigarettes.
Prominent advocate Robert F. Kennedy Jr., the U.S. Secretary of Health, has characterized pouches as “perhaps the safest method of nicotine consumption” and has publicly acknowledged personal use of the product.
Zyn is manufactured by Swedish Match, a subsidiary of Philip Morris International. The Aurora facility currently employs over 120 workers, with ambitions to increase staffing to 500. Additionally, the company invested $232 million to construct a plant in Owensboro, Kentucky, which now employs 340 staff.
Over the past two years, Reynolds has created roughly 1,000 U.S. positions, predominantly via expansion of its pouch‑manufacturing operations, as noted by company spokesperson Luis Pinto.
Altria, the manufacturer of Marlboro cigarettes, produces the On! and On! PLUS brands at its Richmond, Virginia facility. In December, the company secured FDA approval for additional pouch products under a newly streamlined regulatory pathway. (Altria previously operated as Philip Morris before rebranding in 2008 and divesting its international operations to Philip Morris International.)
In December, Swisher, celebrated for its Swisher Sweets cigar line, declared a $135 million expansion of its Jacksonville, Florida, facility, projecting the creation of at least 240 new jobs to support the manufacture of nicotine and caffeine pouches.
Swedish firm WiJo is investing $13 million to establish its inaugural North American pouch manufacturing plant in Lexington, South Carolina.
In South Carolina, a substantial Juul manufacturing site in Lexington County, which had previously received tax abatements and grants, was shuttered following the 2020 federal prohibition on most flavored vaping products; however, county officials subsequently granted tax incentives to WiJo for its newly established pouch facility.
The American tobacco sector has adopted Swedish nicotine‑pouch technology, frequently through acquisitions of domestic Swedish firms.
Altria acquired Helix Sweden in a series of transactions beginning in 2019. In 2022, Philip Morris International purchased Swedish Match for $16 billion.
Garrett Nelson, a senior equity analyst at CFRA, observed that smoke‑free nicotine products, including pouches and vapes, are generating fresh revenue streams for a tobacco industry that had seemed to be in decline.
“These firms are now perceived as growth enterprises, and there is considerable optimism surrounding products such as Zyn and IQOS and other smoke‑free alternatives,” Nelson remarked in an interview.
Zyn presently commands the largest share of the nicotine‑pouch market.
“In the first quarter, Zyn captured 61 percent of the U.S. nicotine‑pouch market by retail dollar value and approximately 56 percent of the market by volume,” Nelson stated.
Although the bulk of Philip Morris International’s revenue still derives from cigarettes, Zyn has contributed to nearly doubling the company’s share price over the past two years.
Yet, despite being marketed as safer alternatives, these products have not alleviated concerns regarding nicotine dependence, which can manifest as irritability, restlessness, difficulty concentrating, anxiety, and alterations in appetite and mood.
The American Lung Association has warned that pouches represent the latest pathway for youth to become addicted, prompting the World Health Organization, in May, to call for stricter regulation; similarly, in April, France prohibited nicotine pouches, creating trade friction with Sweden.
Sam Dashiell, a PMI spokesperson, contested allegations that the products target youth, asserting that pouches are aimed at the approximately 25 million U.S. adults who continue to smoke cigarettes.
“Smoke‑free products offer a preferable option for legally‑age nicotine consumers who might otherwise persist in smoking or using other traditional tobacco products,” Dashiell added.
Advocates of pouches frequently reference Sweden’s pronounced decline in smoking rates, where the transition from cigarettes to pouches is occasionally termed the “Swedish model.”
These products employ nicotine extracted from tobacco leaves or synthesized nicotine, which is increasingly prevalent. Pouches consist of a powdered blend of nicotine, flavorings, and additional ingredients that dissolve within the oral cavity.
Certain health influencers aligned with the MAHA movement — colloquially termed “Zynfluencers” — endorse them as a means to boost energy and cognitive performance. Conservative media personality Tucker Carlson, who co‑owns a pouch brand, promotes the combination of nicotine and caffeine as “the perfect coffee break.”
Dashiell clarified that Philip Morris International does not compensate social‑media influencers for promoting its pouches.
Dr. Gina Kruse, a medicine professor at the University of Colorado Anschutz and a tobacco‑cessation researcher, emphasized the necessity for additional research to elucidate the health effects of nicotine pouches.
“Many of the studies examining cytotoxicity or ingredient composition have been industry‑sponsored,” she noted. “There is an urgent need for more independent research to fully understand the associated risks.”
She further highlighted concerns that pouches could serve as an “on‑ramp” to nicotine dependence, potentially leading users to transition to more harmful products such as cigarettes. “There is certainly concern about flavors that may appeal to young people,” Dr. Kruse said.
A rising concern is that manufacturers are increasing nicotine concentrations, rendering pouches more potent and potentially more addictive, observed Sven Jordt, a distinguished professor at Duke University School of Medicine.
According to Dr. Jordt, a member of the FDA’s Tobacco Products Advisory Committee, the highest nicotine concentrations in leading pouches have risen from six to eight milligrams per unit to ranges of nine to 15 milligrams. “This represents a substantial quantum jump,” he remarked.
The stronger formulations encompass products such as Reynolds American’s Grizzly and Velo Plus, as well as Philip Morris International’s Zyn Ultra, he noted.
“We must investigate the long‑term implications of such usage on the entire digestive system,” he asserted.
“It also introduces another source of artificial sweeteners, each carrying its own set of issues,” Dr. Jordt added. “Questions arise regarding impacts on sleep patterns, fertility, and oral health — particularly gum health — and these warrant rigorous investigation.”
Dr. Jordt cautioned that Sweden serves as a cautionary example: “They now experience an epidemic of oral‑tobacco use, and I fear a similar trend could emerge in the United States.”
The ongoing factory expansions “signal the strategic directions these companies intend to pursue,” he remarked.
Luis Pinto of Reynolds American indicated that the company intends to invest $3.2 billion by 2030 in the production of additional nicotine products, with pouches constituting the primary driver of this expansion.
